On October 20, 2021 CytoReason, an Israeli company developing computational disease models for more efficient drug discovery and development, reported a collaboration with German multinational science and technology company, Merck KGaA, Darmstadt, Germany, to profile one of its leading immuno-oncology drugs (Press release, Merck KGaA, OCT 20, 2021, View Source [SID1234591613]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Multiple drugs created to cure the same disease have varying effects on certain patient populations depending on the drug’s mechanism of action (MoA) and on patients’ characteristics. CytoReason will use its machine learning platform and proprietary computational disease models to verify Merck KGaA, Darmstadt, Germany’s therapeutic hypothesis, providing a deeper analysis of the drug’s MoA.

The company will analyze data from hundreds of patients from phase 1 and 2 studies to identify relevant patient populations, as well as prioritize tumor types for which the drug may be most effective against.

"We are thrilled to be working with the talented team at Merck KGaA, Darmstadt, Germany," said David Harel, CEO and Co-founder of CytoReason. "Merck KGaA, Darmstadt, Germany’s rich medical database and expertise in immuno-oncology will enable us to help create more accurate models of the disease with CytoReason’s advanced AI technology. This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer."